Long-term efficacy: the new gold standard?

S Gerdes¹, J Albrecht^{2

3}

Affiliations

¹ Psoriasis-Center at the Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
² Division of Dermatology, Department of Medicine, Cook County Health, Chicago, IL, USA.
³ Department of Otolaryngology, Division of Dermatology, Rush Medical College, Chicago, IL, USA.

Comment

S Gerdes et al. Br J Dermatol. 2021 Dec.

. 2021 Dec;185(6):1086-1087.

doi: 10.1111/bjd.20715. Epub 2021 Oct 10.

S Gerdes¹, J Albrecht^{2

3}

¹ Psoriasis-Center at the Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
² Division of Dermatology, Department of Medicine, Cook County Health, Chicago, IL, USA.
³ Department of Otolaryngology, Division of Dermatology, Rush Medical College, Chicago, IL, USA.

No abstract available

Comment on

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.
Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Zeng J, Rubant S, Sinvhal R, Zhao Y, Soliman AM, Alperovich G, Leonardi C. Papp KA, et al. Br J Dermatol. 2021 Dec;185(6):1135-1145. doi: 10.1111/bjd.20595. Epub 2021 Sep 21. Br J Dermatol. 2021. PMID: 34157132 Free PMC article. Clinical Trial.

1. Singh S, Thangaswamy A, Thangaraju P, Varthya SB. Efficacy and safety of risankizumab in moderate to severe psoriasis: a systematic review and meta-analysis. Dermatol Ther 2021; 34:e14487.
1. Warren RB, Blauvelt A, Poulin Y et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol 2021; 184:50-9.
1. Nast A, Smith C, Spuls PI et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 2020; 34:2461-98.
1. Papp KA, Lebwohl MG, Puig L et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol 2021; 185:1135-45.
1. Kimball AB, Papp KA, Wasfi Y et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013; 27:1535-45.